Development and Evaluation of Felbamate Loaded Solid Lipid Nanoparticles
Abstract
Full Text:
PDFReferences
Rossella V, Salvatore G, Fulvia C, MariaAngela F, Rosanna DB, Guido M, Paolo B. Epilepsy in neurofibromatosis1. Journal of Child Neurology 2003; 18(5) 338–342.
Adam PO, David HG, Judith LZW. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 2013; 54(10): 1810–1814.
Clorinda A, Teresa M, Fernando P,Patricia F, Ricardo T. Okadaic acid induces epileptic seizures and hyperphosphorylation of the NR2B subunit of the NMDA receptor in rat hippocampus invivo. Experimental Neurology 2002; 177(1): 284–291.
Lucks JS, Muller RH. Medication vehicles made of solid lipid particles (solid lipid nanospheres SLN), in EP0000605497. 1996: Germany.
Saupe A, Wissing SA, Lenk A, Schmidt C Muller RH. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) – Structural investigations on two different carrier systems. Bio-Medical Material Engineering 2005; 15: 393–402.
Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs, International Journal of Pharmaceutics 2002; 242(1-2):121-8.
Jenning V, Thunemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. International Journal of Pharmaceutics 2000; 199(2): 167-77.
Jenning V, Mader K, Gohla S. Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a 1H-NMR study, International Journal of Pharmaceutics 2000; 205(1-2):15-21.
Muller RH. Lipid nanoparticles: recent advances, Advances in Drug Delivery Reviews 2007; 59(6):375-76.
Muller RH, Gohla S, Dingler A, Schneppe T. Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM), in Handbook of Pharmaceutical Controlled Release Technology Wise, D.L., Editor. 2000. p. 359-76.
Burdette David E, Sackellares J Chris. Felbamate Pharmacology and Use in Epilepsy, Clinical Neuropharmacology 1994; 17(5):389-402.
Vicki C, WilliamsA. Selective antagonism of the anticonvulsant effects of felbamate by glycine. European Journal of Pharmacology 1994; 256(2): R9-R10.
Giovambattista DS, Ennio O, Rosalia B, Umberto A, Angela DS. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. European Journal of Pharmacology 1994; 262(1-2): 11-19.
Nancy WK, Jill CG, Chi CC, Tammy DM. Subtype-Selective Antagonism of N-Methyl-D-Aspartate Receptors by Felbamate: Insights into the Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics 1999; 289 (2): 886-894.
Ticku MK, Kamatchi GL, Sofia RD. Effect of Anticonvulsant Felbamate on GABAA Receptor System. Epilepsia1991; 32: 389–391.
Swinyard EA, Sofia RD, Kupferberg HJ. Comparative Anticonvulsant Activity and Neurotoxicity of Felbamate and Four Prototype Antiepileptic Drugs in Mice and Rats. Epilepsia 1986; 27: 27–34
Refbacks
- There are currently no refbacks.